S*BIO
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
0%
0 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
Role: collaborator
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
Role: collaborator
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Role: collaborator
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas
Role: collaborator
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
Role: collaborator
Study of SB939 in Subjects With Myelofibrosis
Role: collaborator
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
Role: lead
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Role: lead
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Role: lead
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Role: lead
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Role: lead
A Single and Multiple-Dose Study of SB1578
Role: lead
All 12 trials loaded